Fine-needle aspiration biopsy in the monitoring of liver allografts.
The diagnosis of acute liver allograft rejection is difficult, as clinical signs or liver function tests are too unspecific. The diagnosis is mainly based on biopsy histology. However, the liver core biopsy may be associated with complications. The fine-needle aspiration biopsy (FNAB) method, originally developed for the monitoring of renal transplants, is a reliable and atraumatic technique to diagnose acute cellular rejection of liver allografts. FNAB makes it possible to quantity the inflammation associated with rejection, and to monitor the response to anti-rejection therapy. Additional information is received from changes in liver parenchymal cells indicating tissue damage and/or possible hepatotoxic effects of the drugs used. In addition, FNAB may be helpful in differential diagnosis of infections, cholestasis or other complications. A good correlation between FNAB findings of acute liver rejection and histology has been reported. However, histological examination is needed to diagnose chronic rejection. Several liver transplant centres now use FNAB technology as a routine diagnostic tool.